# Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

> **NCT01478399** · PHASE1 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PB1023 Injection

## Key facts

- **NCT ID:** NCT01478399
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478399, "Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01478399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*